Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy.
Morales
E
E
Nephrology Department and Infectious Diseases Unit, Hospital 12 de Octubre, Madrid, Spain.
Andrés
A
A
González
E
E
Herrero
J C
JC
Muñoz
M A
MA
Ortiz
M
M
Espejo
B
B
Lumbreras
C
C
Morales
J M
JM
Aguado
J M
JM
D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D000914:Antibodies, Viral; D000961:Antilymphocyte Serum; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D015774:Ganciclovir